Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Herpesviral Fcγ receptors: culprits attenuating antiviral IgG?

Matthias Budt, Henrike Reinhard, Arndt Bigl, Hartmut Hengel*

Robert Koch-Institute, Division of Viral Infections, Nordufer 20, 13353 Berlin, Germany

Received 30 March 2004; received in revised form 17 May 2004; accepted 28 May 2004

Abstract

Production of IgG in response to virus infection is central to antiviral immune effector functions and a hallmark of B cell memory. Antiviral antibodies (Abs) recognising viral glycoproteins or protein antigen displayed on the surface of virions or virus-infected cells are crucial in rendering the virus noninfectious and in eliminating viruses or infected cells, either acting alone or in conjunction with complement. In many instances, passive transfer of Abs is sufficient to protect from viral infection. Herpesviruses (HV) are equipped with a large array of immunomodulatory functions which increase the efficiency of infection by dampening the antiviral immunity. Members of the α- and β-subfamily of the Herpesviridae are distinct in encoding transmembrane glycoproteins which selectively bind IgG via its Fc domain. The Fc-binding proteins constitute viral Fcγ receptors (vFcγRs) which are expressed on the cell surface of infected cells. Moreover, vFcγRs are abundantly incorporated into the envelope of virions. Despite their molecular and structural heterogeneity, the vFcγRs generally interfere with IgG-mediated effector functions like antibody (Ab)-dependent cellular cytolysis, complement activation and neutralisation of infectivity of virions. vFcγRs may thus contribute to the limited therapeutic potency of antiherpesviral IgG in clinical settings. A detailed molecular understanding of vFcγRs opens up the possibility to design recombinant IgG molecules resisting vFcγRs. Engineering IgG with a better antiviral efficiency represents a new therapeutic option against herpesviral diseases.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Viral FcγR; IgG; Herpesvirus; Neutralising antibodies; Immune evasion

1. Introduction: herpesvirus endurance between immune control and immune evasion

Herpesviruses (HV) which are subdivided into three subfamilies (α, β and γ) possess large double-stranded DNA genomes encoding approximately 100–200 genes. HV genomes remain latent in their natural host and can initiate a productive infection from latently infected cells resulting in virus shedding and transmission of virus progeny to a new host [1,2].

During the long history of coevolution and cospeciation with their hosts, HV adopted multiple mechanisms to deal with immune functions that permit establishing a life-long infection with efficient replication and transmission, even in the presence of repeatedly boosted antiviral immune responses [3,4]. Typically, the herpesviral evasion strategy prominently targets those immune responses that attack and contain the virus with the highest efficiency, i.e. CD8+ cytotoxic T cells, natural killer (NK) cells, interferons and Abs. On the other hand, fine-tuning of the host defence strategies to avoid irreversible harm has led to activation of cellular and humoral immunity that tightly control herpesviral infections in a hierarchical but also redundant manner.
To date, eight human herpesviruses, most of which are widespread in the population, are known (listed in Table 1). In the majority of cases, the viruses cause relatively mild or even asymptomatic infections in the immunocompetent host. However, when the intricate balance between viral immune escape and the host’s immunity is lost, uncontrolled virus replication leads to severe disease manifestation as is frequently observed in immunocompromised patients or congenitally infected babies [6].

The complement system and antiviral Abs form a first line of antiviral defence operating before a virion is able to attach to its cellular receptor mediating entry into the host cell to initiate the replicative cycle [7]. The complement system includes proteolytic enzymes, inflammatory proteins, cell surface receptors and proteins that cause cell death through osmotic lysis after insertion into biological membranes. Therefore, a primary requirement is that the complement cascade becomes initiated only in response to infection and cannot be initiated in a random fashion. The complement factors opsonise and lyse Ab-coated viral particles (virolysis) and infected cells (cytolysis) [8,9]. A broad range of host cells expresses several complement-inhibiting proteins which protect tissues from complement-mediated lysis by the inhibition and dissociation of C3 convertases that are central for the amplification of the complement system [10]. Notably, the cell surface expression of CD46 and CD55, two of the complement control proteins (CCP), is strongly enhanced on the plasma membrane of HCMV-infected cells. The upregulated CD55 expression increases the capacity to regulate C3 deposition and thus protects CMV-infected cells from complement-mediated lysis [11]. The selective incorporation of CCPs, i.e. CD55, CD59 and CD46, into virions and the discovery of virus-encoded regulators of complement activation (RCA) underscore the important antiviral role of the complement system [12,13].

Ab neutralisation of virus particles is achieved when bound Abs block the virion from productive interaction with receptors or prevent steps of entry and uncoating [14]. The combination of Abs and complement can activate the classical complement pathway to lyse enveloped viruses. The expression of the vFcγRs protects the HSV virion against this threat by interfering with the recruitment of complement [15].

The arsenal of immuno-modulatory mechanisms of HVs is not restricted to the protection of free virus particles. HV-infected cells are protected from destruction by cytotoxic effector cells and rendered refractory to antiviral cytokines like interferons to ensure efficient virus replication. Recent reviews delineate the bewildering multitude and sophisticated mechanisms of such defence strategies in great detail [3,4,16,17].

### 2. Antiviral effector functions of IgG

Ab neutralisation of viruses is usually demonstrated in vitro when binding of virus-specific Abs leads to a reduction in the number of infectious particles. The mechanisms leading to virus neutralisation are variable and include simple occupancy of virus surface and steric hindrance of a productive interaction with cellular receptors, causing virions to aggregate and thus reducing the concentration of infectious particles, but

| Subfamily | Designation | Synonyms | Genome size (kbp) | FcγRs |
|-----------|-------------|----------|-------------------|-------|
| α         | HHV-1       | Herpes simplex virus 1 | 152   | US8/US7 gE/gl |
|           | HHV-2       | Herpes simplex virus 2 | 152   | US8/US7 gE/gl |
|           | HHV-3       | Varicella-zoster virus | 125   | ORF68/67 gE/gl |
| β         | HHV-5       | Cytomegalovirus        | 235   | UL119–118 gp68 |
|           | HHV-6       | Human herpesvirus 6    | 162   | – gp34 |
|           | HHV-7       | Human herpesvirus 7    | 162   | – – |
| γ         | HHV-4       | Epstein–Barr virus, Lymphocryptovirus | 172 | – – |
|           | HHV-8       | Kaposi’s sarcoma-associated herpesvirus | 160 | – – |

--- not reported.
also complex models involving capping of critical epitopes or induction of conformational changes in viral envelope or capsid structures [18,19]. The enhancing role of the Ab Fc part in direct neutralisation has been explained by an increased avidity of divalent Abs compared to monovalent Fab fragments [20], or its mere size in steric occupation of the virus surface [21].

Of paramount importance is the function of the Ab Fc moiety to recruit the complement system for enhancing in vivo neutralisation, by inducing Ab-dependent complement-mediated lysis (ADCL), and the Fc-receptor-mediated phagocytosis and subsequent destruction of the virus particle by professional antigen-presenting cells. The different ability of the IgG subclasses to bind complement can, therefore, explain the observation of differing neutralising capabilities of Abs sharing common variable regions but having different constant regions [22].

Only a minor fraction of the Ab repertoire that is generated during an immune response against a given virus has neutralising capacity. In addition, there are several other possible ways how Abs can act against viruses. Non-neutralising Abs may promote opsonisation and phagocytosis of a virus or contribute to antiviral defence during later stages of infection, when the virus has already entered the host cell. Recognition of viral antigens on the surface of infected cells by Abs can trigger virus-specific killing by nonspecific cytotoxic effector cells carrying Fc receptor (e.g. NK cells) in a process called Ab-dependent cellular cytotoxicity (ADCC) [23]. The Abs coating a virus-infected target cell attach to the effector cell via its FcγRs, thereby stimulating the release of perforin and granzymes from cytolytic granula which destroy the virus-infected cell.

Moreover, Abs can also block the release of progeny virus from infected cells [24] and have been shown to prevent cell-to-cell spread of viruses [25]. Multimeric IgA and IgM molecules which are transcytosed through epithelial cells have intriguing functions even beyond those of IgG: when such Igs encounter viral antigens inside of cells, they can neutralise virus infectivity even at intracellular sites [26,27].

2.1. IgG in herpesviral infections

While Abs are powerful defence weapons against many viruses, their potency appears restricted against HVs. HVs are commonly able to reactivate productive infection from latency and to reach horizontal transmission and spread in the presence of virus-specific Abs. Likewise, preexisting CMV-specific Abs frequently fail to prevent virus transmission or exogenous superinfection with new virus strains [28,29]. In mouse models of HV infection (mouse CMV, MCMV, murine γ-herpesvirus, MHV-68), Abs were demonstrated to be dispensable for the clearance of primary infection but only to become a limiting factor later on by preventing dissemination of recurrent virus during the post-primary phase of infection [30,31].

The therapeutic effectiveness of hyperimmune sera against HV is limited. It is of value for preventive rather than treatment purposes in certain clinical settings. Here we will discuss the clinical use of antiherpesviral IgG, concentrating on α- and β-HVs that express FcγRs (see Section 4).

2.1.1. HCMV

In congenitally infected newborns, HCMV infection is an important cause of hearing loss as well as cognitive and motor impairments which cannot be effectively prevented or treated by current medical interventions (reviewed in Ref. [32]). Immunity to HCMV can strongly reduce the severity of disease, substantiating the need for a vaccine. In addition, HCMV infection is a major cause of disease and death in immunocompromised patients, e.g. solid organ and bone marrow transplant (BMT) recipients, cancer patients and HIV-infected individuals [33]. Pneumonia, retinitis and lesions of the gastrointestinal tract [34,35] are the most common manifestations of HCMV disease.

The applicability of highly efficient anticytomegaloviral agents like ganciclovir and foscarnet is often limited due to the toxicity of the drugs and the development of drug-resistant HCMV. Therefore, treatment with Abs is frequently a demanding option as additional or replacement therapy. The standard formulations are intravenous infusions of either immunoglobulins pooled from normal human plasma (intravenous Ig, IVIG), or from donors screened for high anti-CMV titers (CMV-IGIV). CMV-IGIV, distributed under the trade names CytoGam® and Cytotect®, is indicated for prophylaxis of CMV disease associated with transplantation of kidney, lung, liver, pancreas and heart [36]. The latest therapeutic regimens include
the combination of antivirals like gancyclovir with CMV-IGIV [37,38], to increase the clinical benefit. The therapeutic value of CMV-IGIV has extensively been studied and reviewed [37,39–42]. Overall, most of the studies were able to demonstrate only a moderate if any reduction in CMV-associated morbidity in defined transplantation settings.

Due to the limited efficacy of polyclonal CMV-IGIV, IgG with a defined reactivity to HCMV antigens have been developed. The immunodominant CMV envelope glycoproteins gB and gH carry most of the neutralising B cell epitopes. They are involved in virus attachment, fusion with host cells and cell-to-cell spread of internal virions [43]. Therefore, gB and gH are obvious candidates for targeted Ab generation. The human monoclonal anti-gH-Ab MSL-109, or sevirumab®, has neutralising capacity but failed to exert any beneficial effect in CMV-seropositive hematopoietic stem cell transplant (HSCT) recipients [44]. Similarly, other anti-HCMV Abs including humanised mouse monoclonal IgGs capable to neutralise HCMV in vitro have not proven effective for therapeutic application in vivo [45,46].

Several approaches using attenuated live virus or viral subunits, like gB, have been undertaken to produce HCMV vaccines, some of which were able to generate gB-specific Abs with demonstrable neutralising capacity [47]. However, no efficient HCMV vaccine is available for clinical purposes so far.

2.1.2. HSV

HSV-1 and HSV-2 share the ability to establish latent infection in sensory neurons and to accomplish recurrent cycles of reactivation, frequently leading to painful labial or genital lesions, respectively. Immunosuppression increases both the risk and the severity of HSV disease through cutaneous dissemination or infection of the central nervous system.

Several lines of circumstantial evidence suggest a protective effect of IgG against HSV-2. First, the risk of virus transmission and the extent of neonatal disease is much lower if the mother has recurrent as compared to primary genital infection [48]. Second, in mouse models of HSV-2 infection, various vaccination protocols generated Abs responses which mediated partial vaginal immunity [49,50]. Recent efforts for vaccine generation employed glycoprotein-D (gD) subunit formulations since gD is a target for neutralising Abs due to the fact that gD directly interacts with HSV receptors on the cell surface to trigger virus entry. Two phase 3 studies of the GlaxoSmithKline HSV-2 gD-subunit vaccine demonstrated a 74% efficacy in preventing occurrence of genital herpes disease in women seronegative for both HSV-1 and HSV-2, while the vaccine was completely ineffective in decreasing HSV-2 infection in men or women seropositive for HSV-1 [51]. Similarly, the CHIRON gB2/gD2 vaccine using similar protein components, but administered with a different adjuvant, was ineffective in preventing HSV-2 infection [52].

2.1.3. VZV

VZV is the common etiological agent of two diseases, varicella (i.e. primary VZV infection or chickenpox) and zoster (i.e. shingles resulting from local reactivation of infection from endogenous VZV genomes in dorsal root ganglia cells). In immunocompetent children varicella is usually a benign, self-limited disease and no general treatment is required. In contrast, non-immune patients belonging to high-risk groups like immunocompromised individuals with exposure to VZV and newborns whose mothers undergo varicella at delivery must receive VZV immunoglobulins (VZIG). In these situations, varicella can take a life-threatening course of infection [53]. While VZIG is clearly efficient in post-exposure prophylaxis, it is not beneficial for therapy of already established VZV infection [54]. Herpes zoster occurs in the presence of VZV-specific Abs. Accordingly, VZIG has no preventive or therapeutic effect on herpes zoster, underlining the resilience of HVs to IgG.

In contrast to HCMV and HSV, active immunisation against VZV can be successfully accomplished with live attenuated virus and its use is approved in the United States since 1995. The VZV vaccine protects against severe varicella, although superinfection of vaccinees with exogenous wild-type VZV strains or reactivation of the vaccine virus may occur [55–57]. Early vaccination studies in children with leukemia suggest that the incidence of zoster might be lower in patients receiving the attenuated Oka vaccine strain than in those infected with wild-type virus [58], but at present it is not clear whether the vaccine will reduce the overall incidence of zoster in healthy vaccinated individuals.
Taken together, antiherpesviral IgG has a certain but limited prophylactic rather than therapeutic effectiveness in the control of HV spread and the progression and severity of disease. Abs alone, however, fail to provide sterile and protective immunity.

3. Cellular FcγRs

Specific surface-expressed cellular receptors are known for all Ig classes, including IgA (FcαR), IgD, (FcδR), IgE (FcεR), IgG (FcγR) and IgM (FcμR). Further Ig receptors exert essential functions in distributing Abs, like the polymeric Ig receptor which transports IgA and IgM across epithelia [59] or the neonatal FcR (FcRn) which delivers maternal IgG to the foetus across the placenta [59]. Recently, a new family consisting of several members of B-cell-expressed FcR homologs has been discovered [60], the precise function of which remains to be elucidated. All classes of cellular FcRs belong to the immunoglobulin supergene family (IgSF) of cell surface molecules. IgSF domains are characterised by a conserved structural motif termed the immunoglobulin fold (reviewed in Ref. [61]) that consists of two layers of antiparallel β-sheets, connected by variable loops. The Ig domain is an autonomous folding unit with manifold occurrence in various kinds of proteins.

The best studied and prototypic FcRs are the IgG-binding FcγRI, FcγRII, and FcγRIII which are exclusively expressed on immune cells and act at the interface of humoral and cellular immunity [62]. FcγRI (CD64) is a transmembrane protein with three extracellular Ig domains of the C2 class of Ig domains (see Fig. 1), which binds to human IgG-Fc with high affinity. The third, juxtamembrane domain

![Diagram of Cellular and Herpesviral FcγRs](image)

Fig. 1. Structural composition of cellular and herpesviral FcγRs. Predicted immunoglobulin supergene family (IgSF)-like domains of cellular (left) and herpesviral (right) FcγRs are colour-coded based on their sequence relatedness. The Ig-like domains of the rodent CMV FcγRs are similarly distant to each of the three domains of cFcγRI. The α-herpesviral FcγR is composed by the gE:gl complex, gE but not gl exhibits a low sequence similarity to the second domain of cFcγRs [92]. The Ig domains of FcγRII and FcγRIII are depicted in their bent orientation that is seen in the crystal structures. The domain arrangement in the other FcγRs is unknown.
is responsible for the high affinity binding while the first two domains alone can mediate only weak binding to IgG [63]. FcγRI is the only Fcγ receptor which strongly binds to monomeric IgG molecules, but does not signal unless IgGs are cross-linked by their specific polymeric ligands.

FcγRII (CD32) and FcγRIII (CD16) preferentially bind polymeric, but not monomeric IgG. They possess two extracellular Ig domains with exhibit closest similarity to the membrane distal domains of FcγRI. The FcγRII isoforms A and B are transmembrane proteins differing in their cytoplasmic portion, while FcγRIII can be expressed as a transmembrane or GPI-linked form (Fig. 1) [64]. The cellular FcγRs use distinct intracytoplasmic motifs for signal transduction into the cell. FcγRIIA and FcγRIIB contain an “immunoreceptor-tyrosine-based activation motif” (ITAM) or “immunoreceptor-tyrosine-based inhibitory motif” (ITIM), respectively, in their cytoplasmic tail. Both motifs are phosphorylated upon receptor engagement but with opposed outcome: While the ITAMs preferentially recruit src-family tyrosine kinases and induce cellular activation, ITIM phosphorylation serves to terminate signaling, mostly via the SH2-domain-containing inositol phosphatase (SHIP). FcγRI and FcγRIII do not contain intrinsic signaling properties but share the common FcR γ chain. Alternatively, FcγRIII can utilise the closely related ζ chain of the T-cell-receptor complex. The FcR γ and the ζ chain each contain an ITAM motif to induce activatory signaling events like the FcγRIIA cytoplasmic moiety [62]. The cross-linking of FcγRI-bound IgG by multivalent antigens, or the binding of preformed immune complexes with FcγRII or FcγRIII, results in clustering of the FcγRF and triggering of a variety of effector mechanisms, such as ADCC, phagocytosis, the release of cytokines, enhanced antigen presentation, and the regulation of Ig production by B cells [62]. Thus, cFcyRs can be functionally considered as antigen receptors.

The Fc portion of Ig forms a well-characterised structure [65]. Its binding to cFcsR is mediated by the membrane-proximal second IgSF domain of cFcRs as revealed by recent studies resolving the crystal structures of FcγRIII in complex with IgG-Fc [66], FcγRIIA complexed with IgG-Fc [67] and FcεRI bound to IgE-Fc [68]. These studies revealed a conserved arrangement of the two Ig domains in a highly bent conformation, uncovering the Ig binding site that is located at the top of the second Ig domain concordantly in all three molecules.

Interestingly, all three FcγRs also occur as soluble forms in the serum, generated either by proteolysis [69], alternative splicing [70], or from separate genes [63]. The functional significance of these isoforms remains to be unravelled.

Studies taking advantage from gene knock-out mice have demonstrated prominent immunoregulatory properties of cFcyRs. Mice devoid of the common FcR γ chain display pleiotropic defects of immune effector cells including impaired macrophage phagocytosis and NK-cell-mediated ADCC as well as defective mast cell-dependent allergic responses [71]. The similar phenotype of FcγRIII-deficient mice illustrates the intimate functional cooperation with the γ chain [72]. The critical regulatory (inhibitory) effect of FcγRIIB on various immune cells is reflected by the hyperreactivity of the immune system in FcγRIIB-deficient animals. Due to the lack of control of B cell proliferation, FcγRIIB-deficient mice develop various forms of autoimmune diseases, either spontaneously or after experimental induction [73,74]. Mast cells from FcγRIIB-deficient animals are hypersensitive to IgG-induced degranulation which culminates in enhanced passive cutaneous anaphylaxis reactions [74].

4. Structure and functions of herpesviral FcγRs

While the cellular FcγRs play a key role in transducing the antiviral potency and specificity of IgG to cellular immunity, various pathogens exploit the same principle of binding the IgG Fc proportion for their own purpose to avoid immune destruction. Examples for Fc-binding proteins are found in gram-positive bacteria [75], in protozoa like schistosomes and trypanosomes [76–78], in coronaviruses [79], hepatitis C virus [80], and most commonly in α- and β-herpesviruses. The last group comprises cytomegaloviruses from different species [81–83], herpes simplex viruses 1 and 2 [84], varicella zoster virus (VZV) [85], the porcine herpesvirus pseudorabies virus (PRV) [86] and presumably also Marek’s disease virus (MDV), an α-herpesvirus infecting chickens,
where proteins homologous to the α-herpesvirus FcγRs are found [87].

4.1. The FcγR of the α-herpesviruses: the gE:gi complex

The ability of HSV-1-infected cells to bind human IgG via its Fc-part was first demonstrated in 1979 [88]. The responsible membrane proteins have subsequently been identified as a complex formed by the glycoproteins gE and gi (Fig. 1) [89], which are encoded by the HSV genes US (unique short) 7/US8 and are dispensable for HSV infection and replication in vitro. Homologous molecules to gE and gi are found in HSV-2 [84], VZV [90], PRV [91] and MDV [87]. gE and gi are exposed on the surface of infected cells and represent also the most abundant structural glycoproteins within the virus envelope. Alignment of a limited portion of the extracellular chain of gE reveals a low sequence similarity with the second domain of cFcγRs [92]. While gE alone binds only aggregated IgG with low affinity, complex formation with gi induces a high affinity receptor which is able to fix monomeric IgG. The HSV-1 gE:gi complex is a heterodimer composed of one molecule each and binds IgG with 1:1 stoichiometry. The affinity for IgG4 is highest with $K_D = 40$ nM [93]. The gE:gi complex binds IgG between the second and third Ig domain, at the Cγ2–Cγ3 interface, which is similar to the Fc-binding site of rheumatoid factors and protein A from Staphylococcus aureus. The importance of H435 of IgG1 for the interaction correlates with the failure to bind many IgG3 subclass allotypes, where the corresponding residue is an arginine [93].

The IgG-binding capability of gE:gi protects HSV-infected cells from ADCC [15]. In mice passively immunised with human anti-HSV-IgG, titers of a gE mutant with a 4-aa insert disrupting the region homologous to mammalian FcγRs were significantly reduced, whereas wild-type HSV remained unaffected. [94]. The minimal modification introduced into the gE mutants affected the IgG-related functions of gE:gi, but did not interfere with the other important gE function, i.e. to mediate direct cell-to-cell spread of nascent virions [95].

The observed protection against antiviral IgG conferred by gE:gi was explained by “antibody bipolar bridging” (ABB) [96] (Fig. 2). According to this model, an IgG molecule recognising an epitope on the surface of a virus-infected cell or a virion via its clonotypic antigen binding Fab domain is simultaneously sequestered by the gE:gi complex via its Fc part. Thus, the IgG Fc domain is prevented from recruiting effector mechanisms, i.e. the complement component C1q or FcγR-expressing cytotoxic effector cells. Several lines of evidence support this hypothesis. First, the competition of binding sites between gE:gi and protein A on the Fc–Cγ2–Cγ3 interface was exploited to demonstrate the masking of the Fc part of IgG through the viral FcγR when bound to HSV-infected cells via its antigen-binding sites [97]. Second, fluorescence resonance energy transfer (FRET) studies have demonstrated that the IgG molecule structure is indeed equipped with sufficient intrinsic flexibility allowing the simultaneous interaction of the Fab and Fc domains with separate ligands displayed on the same cell or virion surface [98].

The VZV gE vFcγR was demonstrated to undergo repeated cycles of receptor-mediated endocytosis and recycling to the plasma membrane of VZV-infected cells. This function depends on a tyrosine residue in a conserved YXXL motif that resembles endocytosis signals [99]. Most interestingly, this process is induced by Fc binding to gE. This finding suggests that the vFcγRs might be designed as a molecular device removing antiviral IgG from the surface of infected cells and thus avoids ADCC and ADCL.

4.2. HCMV FcγRs

Biochemical evidence for an HCMV-induced Fc-binding activity in infected fibroblasts has been collected over almost three decades. IgG binding was detected on the plasma membrane and at intracellular sites of infected cells, as well as in association with HCMV virions [100]. Fc binding was ascribed to various proteins with MWs between 38 and 130 kDa [101]. Only recently, three viral genes encoding two different Fc binding glycoproteins, gp68 and gp34, were identified within the HCMV AD169 genome, both of which are dispensable for viral replication in vitro [83,102]. The equipment with two distinct FcγRs is unique for HCMV and adds another example to the bewildering array of HCMV glycoproteins by which this HV modulates immune functions. The structural composition of the HCMV-encoded vFcγRs
is thoroughly different from the HSV gE:gl heterodimer in that the former represent single-chain type I transmembrane proteins showing significant sequence homology with human cFcγRs in their extraluminal part and are predicted to form IgSF-like domains [83] (Fig. 1).

gp68 is expressed during the early and late phase of HCMV infection from a hitherto unidentified spliced 4.1 kb transcript encompassing the open reading frames UL119 and UL118 from a complex transcription unit, UL115–119. The UL119–118 gene sequence encodes a 347-aa type Ia transmembrane protein with 12 potential N-glycosylation sites. The extracellular domain is predicted to contain a single V-like Immunoglobulin superfamily (IgSF) domain (aa 90–190), including a conserved disulphide bond. In comparison to cellular FcγRs, this domain displays the highest degree of homology to the unique third IgSF domain of FcγRI, the domain conferring the high affinity binding to IgG. Secondary structure algorithms concordantly predict a composition of the gp68 IgSF domain built by seven β-sheets resembling the architecture of the cFcγR IgSF domains [83]. The cytoplasmic domain of gp68 contains a modified ITIM motif (WSYKRL) which may provide a link of gp68 to cellular signaling pathways.

The glycoprotein gp34 is encoded by two identical gene copies, TRL11 and IRL11, the latter of which is present in the duplicated UL5’ (unique long) segment of the laboratory HCMV strain AD169. gp34 is a type Ia transmembrane protein consisting of 234 aa. The extracellular region includes three potential N-glycosylation sites and is predicted to form one IgSF-like domain [83]. This prediction is based on homology with the second domain of the cFcγRIIb, which forms the essential IgG binding moiety of cFcγRs [103]. Important determinants of the three cFcγR binding regions for Fc fragment are conserved in the gp34 sequence. Interestingly, secondary structure calculations predict α-helical interruptions of the β-sheet structure of the IgSF domain, a feature which resembles the FeRn, where α-helices also make important
contributions to the binding interface with hIgG [104]. The cytoplasmic tail of gp34 contains a conserved dileucine motif (DXXXLL) which could indicate a role in intracellular targeting of IgG–gp34 complexes to the endocytic route [105]. Thus, similar to VZV gE:gi, HCMV gp34 might remove bound IgG from the plasma membrane of infected cells to prevent ADCL and ADCC. In contrast to the HSV gE:gi FcγR, HCMV-infected cells were shown to bind to all 4 subclasses of human IgG [106] with graduated affinity (IgG1 \( \geq \) IgG4 \( \geq \) IgG2 \( \geq \) IgG3 [107]). However, the experimental setting used could not dissolve the separate Ig binding properties of gp34 and gp68. These are likely to exist given the different affinities to IgG of distinct mammalian species. Among non-human IgG, the rabbit and, to a minor extent, rat IgG is recognised by gp34 while no binding was observed for gp68 [83,106].

Ultrastructural information revealing the exact binding and contact sites of the HCMV FcγRs and the Fc ligand is not available yet. However, one conclusion with regard to the Fc molecule can be drawn from the fact that Fc-bound vFcγR may benefit from the multitude of stealth mechanisms by which HCMV avoids immune attack.

4.3. Rodent CMV FcγRs

Mouse CMV (MCMV)-infected cells can be decorated with IgG-Fc fragment both intracellularly and on the surface [82]. The genetic basis for this feature is the expression of a single gene, *m138*, coding for an FcγR [82]. The predicted 569-aa type I transmembrane glycoprotein has a calculated mass of 65 kDa and is synthesised during the early and late phase of MCMV replication. The MCMV FcγR is highly glycosylated reaching a MW of 105 kDa, which is reduced to a single band of 68 kDa by deglycosylation. The *m138* protein can be precipitated with mouse IgG-Fc fragment coupled to protein A indicating non-overlapping binding sites as it is the case for the HCMV FcγRs. Alignment of the *m138* sequence with mouse cFcγRs displays a more significant degree of homology and predicts a composition of three FcγR-related IgSF-like domains. (Fig. 1, A. Zimmermann, A. Bigl and H. Hengel, unpublished data).

Two distinct and independent *m138* homologs are present in two different cytomegaloviruses of the rat (RCMV), RCMV strain Maastricht, and RCMV strain England, respectively [110–112]. Preliminary data show that both RCMV-encoded *m138* homologs constitute functional vFcγRs (A. Bigl, M. Budt, S. Voigt, A. Zimmermann, unpublished observation).
MCMV model provides an unique opportunity to assess the biological role of an vFcγR for viral pathogenesis and immune control in vivo. To this end the replication of a MCMV m138 gene deletion mutant, Δm138, was analysed in mice and revealed a dramatically attenuated phenotype in vivo. Surprisingly, in μmt−/− mice lacking the Ig μ chain, defective in B cell development and devoid of Abs, the Δm138 virus was not rescued from attenuation. From this finding it was concluded that the major biological function of the MCMV FcγR must not be related to IgG binding but includes a more prominent IgG-unrelated function as it is known for HSV gE:gI [113]. However, the replacement of the m138 gene sequence by inserting the LacZ gene of Escherichia coli might have affected genes neighbouring m138, which possess common transcription units with m138 [82] and have been implicated in macrophage tropism and efficient MCMV replication in vivo [114]. Furthermore, the viral replication was investigated during primary MCMV infection, where Abs do not contribute to virus immune control [31]. Therefore, the available data do not preclude an Ab-dependent role for the MCMV FcγR at later phases of infection when Abs effectively limit virus dissemination and transmission [5,31]. Studies introducing more subtle changes in the m138 gene without affecting adjacent genes are required to elucidate putative IgG-dependent functions of the MCMV FcγR.

5. Perspective: engineering virus-specific IgGs resisting vFcγRs?

Recent progress in Ab generation technologies allows to select Abs of perfect specificity for defined target structures which can employ distinct effector functions and can be produced in high quantities allowing therapeutic application in patients [115]. Due to the limitations of conventional antiviral drug therapy, the design of potent virus-specific Abs as a therapeutical tool is demanding. Published data support the notion that IgG has an important but certainly not exclusive immunological role against herpesviral infections, and is a potential tool of immunoprophylaxis [19,116]. As outlined above, viral FcγRs are prime suspects for the remarkable ability of HVs to counteract IgG effector functions. Therefore, it is conceivable to assume that antiviral Abs could reach a more potent antiviral efficiency when resisting FcγR-mediated attenuation. According to this concept, an ideal IgG-Fc domain would not be bound by a vFcγR, while still retaining normal affinity to the ligands that recruit protective components of the immune system. As an example, human IgG3 Abs could represent promising candidates for an effective anti-HSV agent since this IgG subclass is a potent activator of the complement cascade [117], but is not blocked by HSV gE:gI [93]. Based on the discrimination of the HSV gE:gI FcγR between hIgG1 allo-types [118], even minimal mutations introduced into recombinant Abs could be sufficient to avoid vFcγR binding, while retaining the functional properties of the molecule with respect to CfcγRs and complement.

HCMV encodes even two FcγRs which bind all human IgG subclasses [83], although with graded affinity, making the design of a discriminating IgG-Fc domain more complex. A detailed understanding of the interaction of the CMV FcγRs with IgG-Fc including ultrastructural analysis would facilitate the modelling of effective IgGs against this virus. If a prototypic IgG-Fc domain fulfilling the requirements of selective interaction is found, this module could be fused to a large number of HCMV-reactive IgG-Fab domains. Such a cocktail of monoclonal recombinant Abs will be necessary to deal with the interstrain diversity of the major HCMV neutralising epitopes present on the glycoproteins gB and gH [119–121] in order to generate widely effective protection.

The MCMV animal model could serve as an optimal test tube to generate experimental evidence in vivo for an IgG-Fc-dependent subversive role of vFcγRs in viral pathogenesis in a natural host. Next, as a proof of principle, MCMV-specific monoclonal Abs with a therapeutic potential [116] are available which will allow to assess the therapeutic benefit of a mutated vFcγR-resistant IgG-Fc module in a variety of infection conditions in vivo. Based on this knowledge, designed IgGs could lead to a new generation of immunopharmacological tools effective against the large burden of human herpesviral diseases.

Acknowledgements

The expert technical assistance of Ingrid Deitemeier is greatly appreciated. We are grateful to Dr. K. Masihi
for critical reading of the manuscript. Our work is supported by the Deutsche Forschungsgemeinschaft through SFB 421/A8 and by the European Community, grant QLRT-2001-01112.

References

[1] Sissons JG, Bain M, Wills MR. Latency and reactivation of human cytomegalovirus. J Infect 2002;44:73–7.
[2] Cohrs RJ, Gilden DH. Human herpesvirus latency. Brain Pathol 2001;11:465–74.
[3] Abendroth A, Arvin A. Varicella-zoster virus immune evasion. Immunol Rev 1999;168:143–56.
[4] Hengel H, Brune W, Koszinowski UH. Immune evasion by cytomegalovirus-surface strategies of a highly adapted opportunistic. Trends Microbiol 1998;6:190–7.
[5] Polic B, Hengel H, Krmpotic A, Trgovich J, Pavic I, Lucaronin P, et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 1998;188:1047–54.
[6] Roizman B, Pellett PE. The family herpesviridae: a brief introduction. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2381–97.
[7] Zinkernagel RM, LaMarre A, Hunziker L, Ochsenbein AF, McCoy KD, et al. Neutralizing antiviral antibody responses. Adv Immunol 2001;79:1–53.
[8] Favoreel HW, Van de Walle GR, Nauwynck HJ, Pensaert MB. Virus complement evasion strategies. J Gen Virol 2003;84:1–15.
[9] Lachmann PJ, Davies A. Complement and immunity to viruses. Immunol Rev 1997;159:69–77.
[10] Smith GP, Smith RA. Membrane-targeted complement inhibitors. Mol Immunol 2001;38:249–55.
[11] Spiller OB, Morgan BP, Tufaro F, Devine DV. Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur J Immunol 1996;26:1532–8.
[12] Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Mocarski Jr ES. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 2002;10:332–9.
[13] Loonen WA, Bruggeman CA, Wiertz EJ. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin Immunol 2001;13:41–9.
[14] Mocarski Jr ES. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 2002;10:332–9.
[15] Loonen WA, Bruggeman CA, Wiertz EJ. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin Immunol 2001;13:41–9.
Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 1994;179:1713–7.

Pass RF, Burke RL. Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection. Semin Pediatr Infect Dis 2002;13:196–204.

Field AK. Human cytomegalovirus: challenges, opportunities and new drug development. Antivir Chem Chemother 1999;10:219–32.

Salomon N, Perlman DC. Cytomegalovirus pneumonia. Semin Respir Infect 1999;14:353–8.

Hoover DR, Peng Y, Saah A, Semba R, Detels RR, Hoover DR, Peng Y, Saah A, Semba R, Detels RR, Detels RR, Rinaldo CH, Jr CR, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114:821–7.

Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000;47:57–77.

Zamora MR. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis 2001;3(Suppl. 2):49–56.

Tzakis AG. Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation. Transpl Infect Dis 2001;3(Suppl. 2):35–9.

Wittes JT, Kelly A, Plante KM. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplant Proc 1996;28:17–24.

Snydman DR. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 2001;3(Suppl. 2):6–13.

Avery RK. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol 1998;13:122–9.

Ruutu T, Ljungman P, Brinch L, Lonnqvist B, Ringden O, et al. No prevention of cytomegalovirus infection by anticytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant 1997;19:233–6.

Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L, et al. Glycoprotein B of human cytomegalovirus promotes viral penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 1993;197:143–58.

Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, et al. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:343–51.

Paar DP, Pollard RB. Immunotherapy of CMV infections. Adv Exp Med Biol 1996;394:145–51.

Hamilton AA, Manuel DM, Grundy JE, Turner AJ, King SI, Adair JR, et al. A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections. J Infect Dis 1997;176:59–68.

Druilhet MW, Malinoski FJ, Fuller SA, Stewart SS, Hoskin S, Duliege AM, et al. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin. Viral Immunol 2000;13:49–56.

Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324:1247–52.

Mohamed SA, Brewer JM, Alexander J, Heath AW, Jennings R. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems. Vaccine 2000;18:2083–94.

Parr MB, Parr EL. Vaginal immunity in the HSV-2 mouse model. Int Rev Immunol 2003;22:43–63.

Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652–61.

Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003;16:96–113.

Fleisher G, Henry W, McSorley M, Arbeiter A, Plotkin S. Life-threatening complications of varicella. Am J Dis Child 1981;135:896–9.

Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med 1974;290:243–5.

Hammerschlag MR, Gershon AA, Steinberg SP, Clarke L, Gelb LD. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis 1989;160:535–7.

Plotkin SA, Starr SE, Connor K, Morton D. Zoster in normal children after varicella vaccine. J Infect Dis 1989;159:1000–1.

Gali K, Lee B, Strine T, Carracher C, Baughman AL, Eaton M, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 2002;347:1909–15.

Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991;325:1545–50.

Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2003;21:96–113.

Davis RS, Wang YH, Kagawa H, Cooper MD. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U S A 2001;98:9772–7.

Williams AF, Barclay AN. The immunoglobulin superfamily: domains for cell surface recognition. Annu Rev Immunol 1998;6:381–405.

Savetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275–90.

Hulett MD, Osman N, McKenzie IF, Hogarth PM. Chimeric Fc receptors identify functional domains of the murine high affinity receptor for IgG. J Immunol 1991;147:1863–8.

Gessner JE, Heiken H, Tamn A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998;76:231–48.

Huber R, Deisenhofer J, Colman PM, Matsushima M, Palm...
W. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 1976;264:415 – 20.

[S6] Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment–Fc gammaRIII complex. Nature 2000;406:267 – 73.

[S7] Maxwell KF, Powell MS, Hulett MD, Barton PA, McKenzie Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. Nat Struct Biol 1999;6:437 – 42.

[S8] Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jar-detzyk TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 2000;406:259 – 66.

[S9] Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J Immunol 1994;152:1314 – 22.

[S10] Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer Torpier G, Capron A, Ouaissi MA. Receptor for IgG(Fc) and protozoa of the Trypanosomatidae. J Exp Med 1981;154:2352 – 5.

[S11] Christensen P, Johansson BG, Kronvall G. Interaction of human beta2-microglobulin on pathogenic but not on nonpathogenic pneumococci. Adv Immunol 1982;32:157– 252.

[S12] Langone JJ. Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumococci. Adv Immunol 1982;32:157– 252.

[S13] Christensen P, Johansson BG, Kronvall G. Interaction of streptococci with the Fc fragment of IgG. Acta Pathol Microbiol Scand, C 1976;84:73 – 6.

[S14] De Miranda-Santos IK, Compos-Neto A. Receptor for immunoglobulin Fc on pathogenic but not on nonpathogenic protozoa of the Trypanosomatidae. J Exp Med 1981;154: 1732– 42.

[S15] Torpier G, Capron A, Ouais MA. Receptor for IgG(Fc) and human beta2-microglobulin on S. mansoni schistosomula. Nature 1979;287:447 – 9.

[S16] Oleszak EL, Leibowitz JL. Fc receptor-like activity of mouse hepatitis virus E2 glycoprotein. Adv Exp Med Biol 1990; 276:51– 8.

[S17] Maillard P, Lavergne JP, Siberil S, Faure G, Roohvand F, Petres S, et al. Fcgamma receptor-like activity of hepatitis C virus core protein. J Biol Chem 2004;279:2430 – 7.

[S18] Eizuru Y, Minamishima Y. Induction of Fc (IgG) receptor(s) by simian cytomegaloviruses in human embryonic lung fibroblasts. Intervirology 1988;29:339 – 45.

[S19] Thale R, Lucin P, Schneider K, Eggers M, Koszinowski UH. Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol 1994;68: 7757 – 65.

[S20] Atalay R, Zimmermann A, Wagner M, Borst E, Benz C, Messerle M, et al. Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol 2002;76:8596 – 608.

[S21] Para MF, Goldstein L, Spear PG. Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. J Virol 1982;41:137 – 44.

[S22] Litwin V, Sandor M, Grose C. Cell surface expression of the varicella-zoster virus glycoproteins and Fc receptor. Virology 1990;178:263 – 72.

[S23] van de Walle GR, Favorcelle HW, Nauwynck HJ, Pensaert MB. Antibody-induced internalization of viral glycoproteins and gE–gl Fc receptor activity protect pseudorabies virus-infected monocytes from efficient complement-mediated lysis. J Gen Virol 2003;84:939 – 48.

[S24] Jang HK, Ono M, Kim TJ, Izumiya Y, Damiani AM, Matsumura T, et al. The genetic organization and transcriptional analysis of the short unique region in the genome of non-oncogenic Marek’s disease virus serotype 2. Virus Res 1998;58:137 – 47.

[S25] Bautte RB, Spear PG. Membrane proteins specified by herpes simplex viruses: V. Identification of an Fc-binding glycoprotein. J Virol 1979; 32:779 – 89.

[S26] Johnson DC, Frame MC, Ligas MW, Cross AM, Stow ND. Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J Virol 1988;62:1347 – 54.

[S27] Litwin V, Jackson W, Grose C. Receptor properties of two varicella-zoster virus glycoproteins, gpl and gplIV, homolo- gous to herpes simplex virus gE and gl. J Virol 1992;66: 3643 – 51.

[S28] Petrovskis EA, Timmins JG, Post LE. Use of lambda gt11 to isolate genes for two pseudorabies virus glycoproteins with homology to herpes simplex virus and varicella-zoster virus glycoproteins. J Virol 1986;60:185 – 93.

[S29] Dubin G, Basu S, Mallory DL, Basu M, Tal-Singer R, Friedman HM. Characterization of domains of herpes simplex virus type 1 glycoprotein E involved in Fc binding activity for immunoglobulin G aggregates. J Virol 1994; 68:2478 – 85.

[S30] Chapman TL, You I, Joseph IM, Bjorkman PJ, Morrison SL, Raghavan M. Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. J Biol Chem 1999;274:6911 – 9.

[S31] Nagashumummag T, Lubinski J, Wang L, Goldstein LT, Weeks BS, Sundaresan P, et al. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 1998;72:5351 – 9.
I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J Virol 1994;68:834–45.

[96] Frank I, Friedman HM. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol 1989;63:4799–88.

[97] Van Vliet KE, De Graaf-Miltenburg LA, Verhoef J, Van Strijp JA. Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells. Immunology 1992;77:109–15.

[98] Zheng Y, Shopes B, Holowka D, Baird B. Dynamic conformations compared for IgE and IgG1 in solution and bound to receptors. Biochemistry 1992;31:7446–56.

[99] Olson JK, Grose C. Endocytosis and recycling of varicella-zoster virus Fc receptor glycoprotein gE: internalization mediated by a YXXL motif in the cytoplasmic tail. J Virol 1997;71:4042–54.

[100] Stannard LM, Hardie DR. An Fc receptor for human immunoglobulin G is located within the tegument of human cytomegalovirus. J Virol 1991;65:3411–5.

[101] Xu B, Murayama T, Ishida K, Furukawa T. Characterization of IgG Fc receptors induced by human cytomegalovirus. J Gen Virol 1989;70(Pt 4):893–900.

[102] Lilley BN, Ploegh HL, Tirabassi RS. Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin Fc-binding protein. J Virol 2001;75:11218–21.

[103] Sondermann P, Kaiser J, Jacob U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J Mol Biol 2001;309:737–49.

[104] Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 1994;372:336–43.

[105] Letourneur F, Klauser RD. A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell 1992;69:1143–57.

[106] Antonsson A, Johansson PJ. Binding of human and animal immunoglobulins to the IgG Fc receptor induced by human cytomegalovirus. J Gen Virol 2001;82:1137–45.

[107] Murayama T, Natsume-Sakai S, Shimokawa K, Furukawa T. Fc receptor(s) induced by human cytomegalovirus bind differentially with human immunoglobulin G subclasses. J Gen Virol 1986;67(7):1475–8.

[108] Kaur A, Kassis N, Hale CL, Simon M, Elliott M, Gomez-Yafal A, et al. Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol 2003;77:5749–58.

[109] McKeating JA, Griffiths PD, Weiss RA. HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor. Nature 1990;343:659–61.

[110] Vink C, Beuken E, Bruggeman CA. Complete DNA sequence of the rat cytomegalovirus genome. J Virol 2000;74:7656–65.

[111] Burns WH, Barbour GM, Sandford GR. Molecular cloning and mapping of rat cytomegalovirus DNA. Virology 1988;166:140–8.

[112] Beisser PS, Kaptein SJ, Beuken E, Bruggeman CA, Vink C. The Maastricht strain and England strain of rat cytomegalovirus represent different betaherpesvirus species rather than strains. Virology 1998;246:341–51.

[113] Cermovic-Mertens I, Messerle M, Milotic I, Szepan U, Kusic N, Krmpotic A, et al. Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol 1998;72:1377–82.

[114] Hanson LK, Slater JS, Karabekian Z, Ciocco-Schmitt G, Campbell AE. Products of US22 genes M140 and M141 confer efficient replication of murine cytomegalovirus in macrophages and spleen. J Virol 2001;75:6292–302.

[115] Borregaard CA, Ohlin M. Antibody evolution beyond Nature. Nat Biotechnol 2002;20:1189–90.

[116] Farrell HE, Shellam GR. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol 1991;72(Pt 1):149–56.

[117] Jefferis R, Pound J, Lund J, Goodall M. Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article. Ann Biol Clin (Paris) 1994;52:57–65.

[118] Armour KL, Atherton A, Williamson LM, Clark MR. The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochem Soc Trans 2002;30:495–500.

[119] Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55–116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990;64:1079–85.

[120] Urban M, Britt W, Mach M. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol 1992;66:1303–11.

[121] Klein M, Schoppe 1, Amvrossiadis N, Mach M. Strain-specific neutralization of human cytomegalovirus isolates by human sera. J Virol 1999;73:878–86.